CellSeed Inc.
Notice of Completion of Allocation of Funds Procured through Exercise of the 24th Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Allocation of funds procured through the exercise of stock acquisition rights has been completed. The use of proceeds comprises 1,387 million yen for research and development and 606 million yen for working capital, totaling 1,993 million yen, with allocation completed in September 2026. Future completion reports will be provided in notices regarding third-party allotments.
Key Figures
- Total Amount Allocated: 1,993 million yen
- Amount Allocated to Research and Development: 1,387 million yen
- Amount Allocated to Working Capital: 606 million yen
AI要約
Completion of Fund Allocation and Disclosure of Uses
This notice reports the completion of allocation for the 24th stock acquisition rights (with exercise price adjustment clause) issued on June 5, 2023. Specifically, of the procured amount of 1,993 million yen, allocations of 1,387 million yen to research and development and 606 million yen to working capital have been completed, and there are no remaining unallocated items. The allocation timing was September 2026. Future allocation status updates will be disclosed sequentially in notices related to the issuance and contract execution of the 25th stock acquisition rights by third-party allotment.
Future Disclosures and Impact
Even after formal notification of allocation completion, investors should follow additional information related to third-party allotments to track the final uses and impacts of the funds. The allocation to research and development and working capital is intended to strengthen long-term growth strategy and operational stability. Investors should await the next disclosure (notice regarding issuance and contract execution of the 25th stock acquisition rights).
CellSeed Inc.
Company overview · Stock price · Financial data · All IR